Scopus BioPharma (Scopus BioPharma) Price-to-Owner-Earnings : (As of Apr. 30, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Scopus BioPharma Price-to-Owner-Earnings?

As of today (2024-04-30), Scopus BioPharma's share price is $0.0011. Scopus BioPharma does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.

The historical rank and industry rank for Scopus BioPharma's Price-to-Owner-Earnings or its related term are showing as below:

SCPS's Price-to-Owner-Earnings is not ranked ^*
in the Biotechnology industry.
Industry Median: 32.37
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-30), Scopus BioPharma's share price is $0.0011. Scopus BioPharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.32. Therefore, Scopus BioPharma's PE Ratio for today is At Loss.

As of today (2024-04-30), Scopus BioPharma's share price is $0.0011. Scopus BioPharma's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.32. Therefore, Scopus BioPharma's PE Ratio without NRI for today is At Loss.

Scopus BioPharma Price-to-Owner-Earnings Historical Data

The historical data trend for Scopus BioPharma's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scopus BioPharma Price-to-Owner-Earnings Chart

Scopus BioPharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Price-to-Owner-Earnings

Get a 7-Day Free Trial

Scopus BioPharma Quarterly Data
	Jun18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Price-to-Owner-Earnings	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Scopus BioPharma's Price-to-Owner-Earnings

For the Biotechnology subindustry, Scopus BioPharma's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scopus BioPharma's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scopus BioPharma's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Scopus BioPharma's Price-to-Owner-Earnings falls into.

Scopus BioPharma Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Scopus BioPharma's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings	=	Share Price	/	Owner Earnings per Share (TTM)
	=	0.0011	/	-0.07
	=

Scopus BioPharma (OTCPK:SCPS) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.

Scopus BioPharma Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Scopus BioPharma's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.

Scopus BioPharma (Scopus BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scopus BioPharma Inc (OTCPK:SCPS) » Definitions » Price-to-Owner-Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

420 Lexington Avenue, Suite 300, New York, NY, USA, 10170

Website

https://www.scopusbiopharma.com

Scopus BioPharma Inc a biotechnology company focused on developing therapeutics targeting the endocannabinoid system. The endocannabinoid system is comprised of chemical compounds, or cannabinoids, that interact with cannabinoid receptors which are located throughout the body. The company product candidates would utilize synthetically-produced cannabinoids as opposed to plant-derived compounds. Its product candidate comprises CO-sTiRNA, which is a STAT3 inhibitor gene therapy and MRI-1867.

Executives

Ira Scott Greenspan	director	888 SEVENTH AVENUE, 9TH FLOOR, NEW YORK NY 10106
Joshua R Lamstein	director, officer: Chairman	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Alan M Horsager	officer: See Remarks	1021 N EVERETT STREET, GLENDALE CA 91207
Robert J Gibson	director, officer: Vice Chairman	71 LANTERN RIDGE RD, NEW CANAAN CT 06840
Lesley Russell	director	41 MOORES RD., FRAZER PA 19355
Iv David Weild	director	22 ORIOLE AVENUE, BRONXVILLE NY 10708
David S. Battleman	director	C/O TRUENORTH LIFESCIENCES, 348 WEST 57TH STREET, #226, NEW YORK NY 10019
David A. Buckel	director	SHARPSPRING, 550 SW 2ND AVENUE, GAINESVILLE FL 32601
Raphael Hofstein	director	C/O HADASSAH, P.O. BOX 12000, JERUSALEM L3 91120
Paul Hopper	director	7982 DOUG HILL, SAN DIEGO CA 92127
Ashish P Sanghrajka	director, officer: President	101 WALL STREET, APARTMENT 19B, NEW YORK NY 10005